Paul M. Yonover, MD, FACS

A rising PSA after treatment discontinuation prompts a PSMA PET that reveals a solitary rib lesion, testing how much confidence clinicians place in a single indeterminate finding.

Adoption of PSMA PET still varies by practice setting, and the panel discusses how visualized disease reshapes conversations with patients accustomed to tracking PSA values alone.

Physiologic PSMA uptake in ganglia, ureters, and other normal structures can mimic disease, and the panel walks through the anatomic pitfalls that most often mislead inexperienced readers.

An indeterminate bone lesion forces clinicians to weigh pretest probability, tracer type, and biopsy risk before committing to a diagnosis, with serial scanning often settling the question over time.

Radiotracer choice, cyclotron versus generator supply chains, and shifting reimbursement policy all shape which patients can access PSMA PET, according to two physicians who built imaging capacity directly into their practices.

Molecular imaging has displaced conventional CT and bone scans as the first-line staging tool in prostate cancer, but a radiation oncologist and a urologist explain where conventional imaging still holds value.

Paul M. Yonover, MD, FACS, offers closing thoughts on unmet needs and clinical challenges surrounding the treatment of prostate cancer.

An expert on prostate cancer discusses treatment considerations for patients with high-risk prostate cancer who have high disease burden and other comorbidities.

A urology specialist reviews the case of a 78-year-old patient with metastatic prostate cancer, analyzes their risk level and prognosis, and discusses frontline treatment.

Paul M. Yonover, MD, FACS, reviews treatment options available for patients with high-risk prostate cancer following radical prostatectomy.

A comprehensive overview of treatment options available for patients with prostate cancer and factors that influence treatment decisions.

An expert on prostate cancer discusses the clinical application of imaging and biomarker testing for patients with prostate cancer.

Paul M. Yonover, MD, FACS, a urology specialist, reviews the case of a 66-year-old man with prostate cancer and offers his initial impressions.

Recent data support the product’s use in protecting organs at risk for radiation exposure.